Germ Cell Tumor Outcomes Vary by Stage and IGCCCG Risk

Key Takeaways
- Among men with testicular or extragonadal germ cell tumors at a southeastern Türkiye referral center, survival was lower with more extensive disease and poorer pretreatment risk.
- No progression or death was observed among men with metastatic seminoma in this cohort; the finding does not establish a cure rate.
- Events in N0M0 pure seminoma included relapses after surveillance or adjuvant treatment and a death unrelated to relapse.
Investigators retrospectively included 83 eligible adult men diagnosed with germ cell tumors from 2007 through 2025 at Dicle University Faculty of Medicine in Diyarbakır. They re-verified pathology, imaging, laboratory, chemotherapy, and death records. Disease extent was classified as N0M0, stage II with nodal involvement, or stage III with distant metastasis; some tumors had extragonadal primaries. Pathology reports determined histology, with mixed tumors grouped as nonseminoma. International Germ Cell Cancer Collaborative Group (IGCCCG) risk was recalculated for nodal or metastatic disease from primary and metastatic sites and pretreatment markers rather than existing risk codes; supplementary age and lactate dehydrogenase criteria from the updated classification were not applied. Overall survival (OS) ran from diagnosis to death, and progression-free survival (PFS) to progression, relapse, or death. The same composite in N0M0 disease was termed event-free survival (EFS). Kaplan–Meier estimates were descriptive, without adjusted modeling. Median follow-up in nodal or metastatic disease was 75.4 months, and all men in that group received initial cisplatin-based chemotherapy.
In nodal or metastatic disease, five-year OS was 82.3% (95% confidence interval [CI], 69.6–90.1), and five-year PFS was 63.1% (95% CI, 48.5–74.6). Five-year OS was higher in stage II than stage III disease, at 95.7% versus 70.5%; PFS was also lower with distant disease.
Nearly half of metastatic nonseminomas were classified as IGCCCG poor risk. Five-year OS decreased from 100% in good-risk disease, with no observed deaths, to 60.2% in poor-risk disease; the intermediate-risk estimate lay between them. The good-risk estimate does not guarantee survival, and PFS also worsened across risk groups. In N0M0 disease, four events occurred, all among patients with pure seminoma: surveillance relapses, a relapse after single-agent adjuvant carboplatin, and a pulmonary-thromboembolism death without relapse.
Histology comparisons were unadjusted across groups differing in stage, IGCCCG risk, and initial management. The small N0M0 seminoma subgroup included a noncancer death, while the metastatic seminoma subgroup without observed events was also small. Referral selection and small strata constrain interpretation. Nonstandardized disease assessments and censoring at the last visit could overestimate PFS or EFS. Elevated-marker N0M0 cases could not reliably be separated into stage I and IS, and pathology slides received no central review. Investigators could not establish whether very early deaths after chemotherapy reflected disease or treatment toxicity. Selection and survival bias also preclude attributing transplant recipients’ outcomes to transplantation.
The authors concluded that more advanced clinical stage and poorer recalculated IGCCCG risk tracked with worse outcomes in this regional cohort, where poor-risk metastatic nonseminoma was frequent. Histology-specific contrasts remained descriptive rather than evidence of an independent histologic effect.
Clinician Questions
What was the status of germ cell tumor patients given high-dose chemotherapy with autologous transplantation after progression?
Five of nine recipients of high-dose chemotherapy with autologous transplantation for relapsed or progressive germ cell tumors were alive at last follow-up. This selected, observational group does not establish a treatment effect of transplantation.
How did investigators handle elevated AFP in pathology-confirmed pure seminoma?
For men whose original pathology reports confirmed pure seminoma, mild pretreatment alpha-fetoprotein (AFP) elevations did not change the main pathology-based classification. In a sensitivity analysis, investigators reassigned the three men with AFP above 10 ng/mL to nonseminoma. They could not establish why AFP was elevated, and there was no central slide review.
When was chemotherapy classified as adjuvant rather than first-line in men with germ cell tumors?
Among men with testicular or extragonadal germ cell tumors, chemotherapy after orchiectomy and before relapse was classified as adjuvant for N0M0 disease but as first-line treatment for N+ or M1 disease. Chemotherapy after relapse during surveillance was classified as relapse treatment; these labels do not establish that either approach improved outcomes.
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.